Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIOUS-II
NCT05635227Recruiting
- Sponsor
- Rigshospitalet
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexamethasone and olanzapine in postoperative delirium (POD) and Systemic Inflammatory Response Syndrome (SIRS) (8 arms), sponsored by Rigshospitalet. Primary endpoint: Days alive and outside hospital within 90 days. Started Nov 2022; status: recruiting.
02
Drugs
dexamethasoneolanzapine
03
Conditions
postoperative delirium (POD)Systemic Inflammatory Response Syndrome (SIRS)
Beyond the preview
Go deeper on NCT05635227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635227.